Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.
Samuel J KlempnerDaniel V T CatenacciPublished in: Cancer discovery (2019)
Sanchez-Vega and colleagues prospectively demonstrate that both intra- and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and MET dictate sensitivity to the pan-HER inhibitor afatinib in a phase II trial of trastuzumab-refractory HER2-amplified gastroesophageal adenocarcinomas. Rapid autopsy, tissue-based genomic characterization, and molecular imaging provide complementary information and may aid in selecting optimal patients for targeted monotherapy versus combination approaches in gastroesophageal adenocarcinomas.See related article by Sanchez-Vega et al., p. 199.
Keyphrases
- epidermal growth factor receptor
- end stage renal disease
- tyrosine kinase
- small cell lung cancer
- newly diagnosed
- ejection fraction
- prognostic factors
- open label
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- advanced non small cell lung cancer
- gene expression
- cancer therapy
- drug delivery
- copy number
- health information
- quantum dots
- study protocol